Response of intracellular proteolysis to alteration of bacterial protein and the implications in metabolic regulation.
An assessment has been made of the extent to which the breakdown of microbial cellular proteins is regulated by their metabolic state or function. For this purpose, a number of agents and conditions that alter the synthesis, structure, or utility of cellular protein were examined for the effect on their lability. In Escherichia coli, 5-fluorouracil, p-fluorophenylalanine, norleucine, canavanine, thienylalanine, and puromycin, which engender nonfunctional cellular protein en masse, and ultraviolet irradiation increase the breakdown rate of proteins synthesized in their presence as much as two- to threefold without altering the general capacity for proteolysis. The effects are complicated by, but experimentally distinguishable from, secondary changes in proteolysis that accompany growth inhibition. In contrast, no potentiation of proteolysis is elicited by the presence of suppressor genes, by the administration of heat, or by the biosynthetic alterations attending large changes in the conditions of cultivation or by those attending bacteriophage infection. Thus, although mass perturbations in protein conformation are catabolically distinguishable, the more individual and limited conformational modifications that might occur in disuse do not appear to be the primary determinants of the protein turnover rate. In Bacillus subtilis, turnover synthesis of protein during starvation is as susceptible to treatment with actinomycin D as that during growth. Treatment alters neither the rate of intracellular proteolysis nor the catabolic pattern of the modicum of proteins that are still synthesized. It is concluded that there is no correlation between metabolic stability of protein and the stability of its messenger ribonucleic acid.
D000409:Alanine / Q000494:pharmacology; D001412:Bacillus subtilis / Q000187:drug effects; D001426:Bacterial Proteins / Q000378:metabolism*; D002172:Canavanine / Q000494:pharmacology; D002247:Carbon Isotopes; D002701:Chloramphenicol / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects* / Q000378:metabolism* / Q000528:radiation effects; D005472:Fluorouracil / Q000494:pharmacology; D007930:Leucine / Q000494:pharmacology; D010649:Phenylalanine / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology; D013696:Temperature; D014466:Ultraviolet Rays
D001426:Bacterial Proteins; D002247:Carbon Isotopes; D003609:Dactinomycin; D002172:Canavanine; D010649:Phenylalanine; D011691:Puromycin; D002701:Chloramphenicol; D007930:Leucine; D000409:Alanine; D005472:Fluorouracil